Covered recipient · General Payments record
BASIL T DARRAS
Allopathic & Osteopathic Physicians Psychiatry & Neurology Neurology with Special Qualifications in Child Neurology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2019 · Entire year
$42,464.18
106 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2019 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Consulting Fee | $19,340.00 | 7 |
| Education | $12,180.19 | 52 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $6,369.81 | 24 |
| Travel and Lodging | $3,944.67 | 12 |
| Food and Beverage | $629.51 | 11 |
By paying entity
PY2019 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| F. Hoffmann-La Roche AG | $15,059.85 | 34 |
| AveXis | $11,954.36 | 50 |
| Sarepta Therapeutics, Inc. | $8,788.61 | 10 |
| Biogen, Inc. | $5,664.44 | 6 |
| Roche Products Limited | $830.00 | 1 |
| VERTEX PHARMACEUTICALS INCORPORATED | $166.09 | 4 |
| Retrophin, Inc. | $0.83 | 1 |
Page 3 of 3; records 101–106 of 106 matching records. This page contains 6 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
BASIL T DARRAS
NPI 1538191309 · CMS profile ID 296783
Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Neurology with Special Qualifications in Child Neurology
BOSTON, MA
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 3 of 3; records 101–106 of 106 matching records. This page contains 6 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1538191309?year=2019&recipient=provider&page=3#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- BASIL T DARRAS, NPI 1538191309, CMS profile ID 296783. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–106 of 106 matching records. This page contains 6 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1538191309?year=2019&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
- APA 7
- IndustryPayments. (2026). BASIL T DARRAS, NPI 1538191309, CMS profile ID 296783. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–106 of 106 matching records. This page contains 6 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1538191309?year=2019&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
- Bluebook
- BASIL T DARRAS, NPI 1538191309, CMS profile ID 296783, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–106 of 106 matching records. This page contains 6 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1538191309?year=2019&recipient=provider&page=3#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2019
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30
106 matching records · $42,464.18 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 101–106 of 106.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| F. Hoffmann-La Roche AG | $326.06 | 03/31/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 681073329 | CMS |
| F. Hoffmann-La Roche AG | $222.74 | 03/31/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 681073501 | CMS |
| F. Hoffmann-La Roche AG | $278.08 | 03/31/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 681075343 | CMS |
| F. Hoffmann-La Roche AG | $286.38 | 03/31/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 681075449 | CMS |
| Sarepta Therapeutics, Inc. | $800.00 | 03/18/2019 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 681675063 | CMS |
| F. Hoffmann-La Roche AG | $2,580.00 | 01/24/2019 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 681075943 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Recipient | $12,254.16 | 11 |
| PY2025 | Principal investigator | $1,105,304.26 | 25 |
| PY2024 | Recipient | $6,658.85 | 6 |
| PY2024 | Principal investigator | $1,310,794.79 | 25 |
| PY2023 | Recipient | $5,103.44 | 8 |
| PY2023 | Principal investigator | $819,329.30 | 28 |
| PY2022 | Recipient | $845.12 | 1 |
| PY2022 | Principal investigator | $1,683,792.83 | 37 |
| PY2021 | Recipient | $4,968.04 | 12 |
| PY2021 | Principal investigator | $633,334.72 | 28 |
| PY2020 | Recipient | $22,007.37 | 35 |
| PY2020 | Principal investigator | $1,216,117.83 | 39 |
| PY2019 | Principal investigator | $1,420,313.73 | 39 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
36 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | PTC Therapeutics, Inc. | $2,000.00 | 12/16/2025 | Covered Recipient Teaching Hospital CHILDRENS HOSPITAL CORPORATION | AN OPEN-LABEL, SAFETY STUDY FOR ATALUREN (PTC124) PATIENTS WITH NONSENSE MUTATION DYSTROPHINOPATHY | No dispute reported | 06/30/2026 | 1249092611 |
| Principal investigator 1 | Biogen, Inc. | $50,800.00 | 12/01/2025 | Covered Recipient Teaching Hospital Childrens Hospital Corporation | An Open Label, Single Cohort Study to Assess the Pharmacokinetic Profile of Nusinersen (BIIB058) Administered Via the ThecaFlex DRx System (PIERRE-PK) | No dispute reported | 06/30/2026 | 1236947112 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $30.00 | 12/01/2025 | Covered Recipient Teaching Hospital Childrens Hospital Corporation | Long-term Follow-up of Patients With Spinal Muscular Atrophy Treated With OAV101 IT or OAV101 IV in Clinical Trials | No dispute reported | 06/30/2026 | 1190297341 |
| Recipient | F. Hoffmann-La Roche AG | $504.44 | 10/21/2025 | Covered Recipient Physician | Safety update: Risdiplam clinical trial program for spinal muscular atrophy (SMA) | No dispute reported | 06/30/2026 | 1211534819 |
| Recipient | F. Hoffmann-La Roche AG | $501.16 | 10/10/2025 | Covered Recipient Physician | RO7034067 IN ADULT AND PEDIATRIC PATIENTS WITH SPINAL MUSCULAR ATROPHY | No dispute reported | 06/30/2026 | 1211534816 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $12,425.30 | 10/03/2025 | Covered Recipient Teaching Hospital Childrens Hospital Corporation | A Long-term Follow-up Study of Patients in the Clinical Trials for Spinal Muscular Atrophy Receiving AVXS-101 | No dispute reported | 06/30/2026 | 1190296493 |
| Principal investigator 1 | PTC Therapeutics, Inc. | $2,625.00 | 09/26/2025 | Covered Recipient Teaching Hospital CHILDRENS HOSPITAL CORPORATION | AN OPEN-LABEL, SAFETY STUDY FOR ATALUREN (PTC124) PATIENTS WITH NONSENSE MUTATION DYSTROPHINOPATHY | No dispute reported | 06/30/2026 | 1249092599 |
| Principal investigator 1 | PTC Therapeutics, Inc. | $236.25 | 09/26/2025 | Covered Recipient Teaching Hospital CHILDRENS HOSPITAL CORPORATION | AN OPEN-LABEL, SAFETY STUDY FOR ATALUREN (PTC124) PATIENTS WITH NONSENSE MUTATION DYSTROPHINOPATHY | No dispute reported | 06/30/2026 | 1249092601 |
| Principal investigator 1 | Genentech, Inc. | $64,005.00 | 09/10/2025 | Non-covered Recipient Entity BOSTON CHILDRENS HOSPITAL RESEARCH FINANCE | GYM329 RO7204239 IN COMBINATION WITH RISDIPLAM RO7034067 IN PATIENTS WITH SPINAL MUSCULAR ATROPHY | No dispute reported | 06/30/2026 | 1211581965 |
| Principal investigator 1 | PTC Therapeutics, Inc. | $956.25 | 08/29/2025 | Covered Recipient Teaching Hospital CHILDRENS HOSPITAL CORPORATION | AN OPEN-LABEL, SAFETY STUDY FOR ATALUREN (PTC124) PATIENTS WITH NONSENSE MUTATION DYSTROPHINOPATHY | No dispute reported | 06/30/2026 | 1249092595 |
| Recipient | F. Hoffmann-La Roche AG | $582.97 | 07/21/2025 | Covered Recipient Physician | Baseline demographics and clinical characteristics of risdiplam-treated individuals with SMA from the Pediatric Neuromuscular Clinical Research (PNCR) registry | No dispute reported | 06/30/2026 | 1211534813 |
| Recipient | F. Hoffmann-La Roche AG | $459.04 | 07/18/2025 | Covered Recipient Physician | FIREFISH Parts 1 and 2: 5-year efficacy and safety of risdiplam in Type 1 SMA | No dispute reported | 06/30/2026 | 1211534804 |
| Recipient | F. Hoffmann-La Roche AG | $209.41 | 07/18/2025 | Covered Recipient Physician | Real-world risdiplam effectiveness in adults with SMA from the Pediatric Neuromuscular Clinical Research (PNCR) registry | No dispute reported | 06/30/2026 | 1211534809 |
| Principal investigator 1 | PTC Therapeutics, Inc. | $3,750.00 | 06/30/2025 | Covered Recipient Teaching Hospital CHILDRENS HOSPITAL CORPORATION | AN OPEN-LABEL, SAFETY STUDY FOR ATALUREN (PTC124) PATIENTS WITH NONSENSE MUTATION DYSTROPHINOPATHY | No dispute reported | 06/30/2026 | 1249092589 |
| Principal investigator 1 | PTC Therapeutics, Inc. | $866.25 | 06/30/2025 | Covered Recipient Teaching Hospital CHILDRENS HOSPITAL CORPORATION | AN OPEN-LABEL, SAFETY STUDY FOR ATALUREN (PTC124) PATIENTS WITH NONSENSE MUTATION DYSTROPHINOPATHY | No dispute reported | 06/30/2026 | 1249092591 |
| Recipient | F. Hoffmann-La Roche AG | $1,097.92 | 06/25/2025 | Covered Recipient Physician | Baseline demographics and clinical characteristics of risdiplam-treated individuals with SMA from the Pediatric Neuromuscular Clinical Research (PNCR) registry | No dispute reported | 06/30/2026 | 1211534824 |
| Recipient | F. Hoffmann-La Roche AG | $259.30 | 06/06/2025 | Covered Recipient Physician | Real-world risdiplam effectiveness in adults with SMA from the Pediatric Neuromuscular Clinical Research (PNCR) registry | No dispute reported | 06/30/2026 | 1211534828 |
| Principal investigator 1 | Genentech, Inc. | $49,812.00 | 05/27/2025 | Non-covered Recipient Entity BOSTON CHILDRENS HOSPITAL RESEARCH FINANCE | GYM329 RO7204239 IN COMBINATION WITH RISDIPLAM RO7034067 IN PATIENTS WITH SPINAL MUSCULAR ATROPHY | No dispute reported | 06/30/2026 | 1211581962 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $76,413.90 | 05/23/2025 | Covered Recipient Teaching Hospital Childrens Hospital Corporation | A Long-term Follow-up Study of Patients in the Clinical Trials for Spinal Muscular Atrophy Receiving AVXS-101 | No dispute reported | 06/30/2026 | 1190294912 |
| Principal investigator 1 | PTC Therapeutics, Inc. | $236.25 | 04/30/2025 | Covered Recipient Teaching Hospital CHILDRENS HOSPITAL CORPORATION | AN OPEN-LABEL, SAFETY STUDY FOR ATALUREN (PTC124) PATIENTS WITH NONSENSE MUTATION DYSTROPHINOPATHY | No dispute reported | 06/30/2026 | 1249092583 |
| Recipient | F. Hoffmann-La Roche AG | $768.70 | 03/31/2025 | Covered Recipient Physician | Real-world risdiplam effectiveness in adults with spinal muscular atrophy (SMA) from the Pediatric Neuromuscular Clinical Research (PNCR) registry | No dispute reported | 06/30/2026 | 1211534832 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $2,137.50 | 03/19/2025 | Covered Recipient Teaching Hospital Childrens Hospital Corporation | 4045-301 | No dispute reported | 06/30/2026 | 1223610453 |
| Recipient | Novartis Pharma AG | $2,825.00 | 03/18/2025 | Covered Recipient Physician | COAV101B12301 | No dispute reported | 06/30/2026 | 1248109103 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $2,500.00 | 03/12/2025 | Covered Recipient Teaching Hospital Childrens Hospital Corporation | 4045-301 | No dispute reported | 06/30/2026 | 1223610455 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $750.00 | 03/12/2025 | Covered Recipient Teaching Hospital Childrens Hospital Corporation | 4045-301 | No dispute reported | 06/30/2026 | 1223610457 |
| Principal investigator 1 | PTC Therapeutics, Inc. | $866.25 | 02/27/2025 | Covered Recipient Teaching Hospital CHILDRENS HOSPITAL CORPORATION | AN OPEN-LABEL, SAFETY STUDY FOR ATALUREN (PTC124) PATIENTS WITH NONSENSE MUTATION DYSTROPHINOPATHY | No dispute reported | 06/30/2026 | 1249092579 |
| Principal investigator 1 | Genentech, Inc. | $314,033.00 | 02/14/2025 | Non-covered Recipient Entity BOSTON CHILDRENS HOSPITAL RESEARCH FINANCE | GYM329 RO7204239 IN COMBINATION WITH RISDIPLAM RO7034067 IN PATIENTS WITH SPINAL MUSCULAR ATROPHY | No dispute reported | 06/30/2026 | 1211581958 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $34,336.21 | 02/14/2025 | Covered Recipient Teaching Hospital Childrens Hospital Corporation | 4045-301 | No dispute reported | 06/30/2026 | 1223610451 |
| Recipient | Novartis Pharmaceuticals Corporation | $1,322.08 | 01/31/2025 | Covered Recipient Physician | Research Publication/Writing Support | No dispute reported | 06/30/2026 | 1190293431 |
| Recipient | Novartis Pharmaceuticals Corporation | $3,724.14 | 01/30/2025 | Covered Recipient Physician | STRENGTH | No dispute reported | 06/30/2026 | 1190293427 |
| Principal investigator 1 | PTC Therapeutics, Inc. | $360.00 | 01/30/2025 | Covered Recipient Teaching Hospital CHILDRENS HOSPITAL CORPORATION | AN OPEN-LABEL, SAFETY STUDY FOR ATALUREN (PTC124) PATIENTS WITH NONSENSE MUTATION DYSTROPHINOPATHY | No dispute reported | 06/30/2026 | 1249092575 |
| Principal investigator 1 | Biogen, Inc. | $33,248.82 | 01/23/2025 | Covered Recipient Teaching Hospital Childrens Hospital Corporation | An Open-Label Extension Study for Patients With Spinal Muscular AtrophyWho Previously Participated in Investigational Studies of ISIS 396443 | No dispute reported | 06/30/2026 | 1236947250 |
| Principal investigator 1 | Biogen, Inc. | $56,468.00 | 01/10/2025 | Covered Recipient Teaching Hospital Childrens Hospital Corporation | Escalating Dose and Randomized, Controlled Study of Nusinersen (BIIB058) in Participants With Spinal Muscular Atrophy | No dispute reported | 06/30/2026 | 1236947388 |
| Principal investigator 1 | Biogen, Inc. | $161,224.00 | 01/08/2025 | Covered Recipient Teaching Hospital Childrens Hospital Corporation | A Phase 3b Study to Evaluate Higher Dose Nusinersen (BIIB058) in Patients with Spinal Muscular Atrophy Previously Treated with Risdiplam | No dispute reported | 06/30/2026 | 1236947564 |
| Principal investigator 1 | Biogen, Inc. | $234,894.28 | 01/06/2025 | Covered Recipient Teaching Hospital Childrens Hospital Corporation | A Long-Term Extension Study of Nusinersen (BIIB058) Administered at Higher Doses in Participants With Spinal Muscular Atrophy Who Previously Participated in an Investigational Study with Nusinersen. | No dispute reported | 06/30/2026 | 1236948082 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $330.00 | 01/01/2025 | Covered Recipient Teaching Hospital Childrens Hospital Corporation | Long-term Follow-up of Patients With Spinal Muscular Atrophy Treated With OAV101 IT or OAV101 IV in Clinical Trials | No dispute reported | 06/30/2026 | 1190294918 |